Based on the literature and our findings of low irisin levels in MS patients, we suggest that a comprehensive approach—incorporating pharmacotherapy along with tailored physical activity and dietary interventions—may help modulate inflammation and prevent muscle loss. This evidence concerns the gene FNDC5 and myeloid sarcoma.